Why is the Ramsay (ASX:RHC) share price so volatile today?

COVID is hitting Ramsay's operations…

| More on:
A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has pulled back from its intraday highs in afternoon trade.

At the time of writing, the private hospital operator's shares are up 0.5% to $68.00.

This compares to a 2% gain for the Ramsay share price in earlier trade.

What did Ramsay announce?

This afternoon Ramsay released an update in relation to the impact that COVID-19 restrictions are having on its operations.

It notes that the NSW Ministry of Health will introduce restrictions on non-urgent overnight Category 2 and Category 3 elective surgeries at all private hospitals in the state effective 10 January.

Category 2 admission relates to a condition which is not likely to deteriorate quickly or become an emergency within 90 days. Whereas a Category 3 admission is unlikely to deteriorate quickly and has little potential to become an emergency within 365 days.

In addition to this, Ramsay highlights that similar changes were made by the Victorian Department of Health and Human Services (DHHS) to surgical restrictions on 6 January. Elective surgery is now restricted to urgent elective surgery procedures.

Further, neither the DHHS nor the NSW Ministry of Health have provided a date for when these restrictions will end and Ramsay will be able to return to business as usual.

What will the impact be?

Ramsay has warned that these and previous surgical restrictions will have a material impact on its earnings in FY 2022. For example, it notes that in the first quarter, COVID related disruptions and costs impacted its Australian earnings by $55 million.

And while January is the seasonally quietest month of the year in the Australian business, it remains unclear when the current wave of Omicron cases will subside and Ramsay will be able to operate as normal again. This could see the restrictions creep into busier months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Why I'm taking a closer look at ResMed shares

The ResMed share price hasn’t escaped recent market volatility. Is it time to buy?

Read more »

Health professional working on his laptop.
Healthcare Shares

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

Let's see what the broker is saying about these healthcare stocks.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Own CSL shares? You're getting a dividend paycheque today

There's a silver lining to today's sell-off.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

How this Trump appointee could pressure the CSL share price

A leading expert believes Donald Trump isn’t doing CSL shareholders any favours.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Top broker says Mesoblast shares can rocket 100%

Big returns could be on offer from this biotech according to Bell Potter.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

A leading expert forecasts more growth ahead for this $32 billion ASX 200 healthcare company.

Read more »

A scientist examining test results.
Healthcare Shares

1 ASX dividend stock down 43% I'd buy right now

This business could provide both dividends and growing, defensive earnings.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Why FDA approval could turn this ASX All Ords company into a multibagger

Despite surging more than 230% in the past year, this company might be on its way to becoming a much…

Read more »